PIVKA-II is a candidate marker for monitoring the effects of the oral anticoagulant warfarin

Clinical Biochemistry

Volumn 43, Issue 13-14, 2010, Pages 1177-1179

  Lee, Woochang ^a   Chung, Hee Jung ^a   Kim, Sollip ^a   Jang, Seongsoo ^a   Park, Chan Jeoung ^a   Chi, Hyun Sook ^a   Chun, Sail ^a   Min, Won Ki ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Drug monitoring; International normalized ratio; PIVKA II (protein induced by vitamin K absence or antagonist II); Warfarin

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; PROTEIN PRECURSOR; PROTHROMBIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; DRUG EFFECT; DRUG MONITORING; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT RESPONSE;

AGED; ANTICOAGULANTS; BIOLOGICAL MARKERS; DRUG MONITORING; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; PROTEIN PRECURSORS; PROTHROMBIN; WARFARIN;

EID: 77956176663     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.06.022     Document Type: Article

References (10)

1. Loebstein R., Yonath H., Peleg D., et al. Interindividual variability in sensitivity to warfarin-Nature or nurture?. Clin Pharmacol Ther 2001, 70:159-164.
2. Kimmel S.E. Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother 2008, 9:677-686.
3. Chan E., Aarons L., Serlin M., Breckenridge A., Rowland M. Inter-relationship among individual vitamin K-dependent clotting factors at different levels of anticoagulation. Br J Clin Pharmacol 1987, 24:621-625.
4. Hirsh J., Dalen J.E., Deykin D., Poller L. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992, 102:312S-326S.
5. Costa I.M., Soares P.J., Afonso M., Ratado P., Lanaot J.M., Falcao A.C. Therapeutic monitoring of warfarin: the appropriate response marker. J Pharm Pharmacol 2000, 52:1405-1410.
6. Presnell S.R., Stafford D.W. The vitamin K-dependent carboxylase. Thromb Haemost 2002, 87:937-946.
7. Baek Y.H., Lee J.H., Jang J.S., et al. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology 2009, 56:763-767.
8. Umeki S., Umeki Y. Levels of acarboxy prothrombin (PIVKA-II) and coagulation factors in warfarin-treated patients. Med Lab Sci 1990, 47:103-107.
9. Wen M.S., Lee M., Chen J.J., et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008, 84:83-89.
10. Iwahashi H., Iwahashi M., Kimura M., Zaitsu R., Tashiro T., Morita T. Clinical utility of highly sensitive measurement of the PIVKA-II in anticoagulant therapy patients treated with warfarin. Fukuoka Daigaku igaku kiy? 2007, 34:65-70.